Long‐term safety and efficacy of tofogliflozin as add‐on to insulin in patients with type 2 diabetes: Results from a 52‐week, multicentre, randomized, double‐blind, open‐label extension, Phase 4 study in Japan (J‐STEP/INS)

AIMS: To evaluate the long‐term safety and efficacy of tofogliflozin as an add‐on treatment to insulin over 52 weeks. MATERIALS AND METHODS: This 52‐week, multicentre, Phase 4 study consisted of a 16‐week, randomized, double‐blind, placebo‐controlled phase and a 36‐week open label extension phase (N...

Descripción completa

Detalles Bibliográficos
Autores principales: Terauchi, Yasuo, Tamura, Masahiro, Senda, Masayuki, Gunji, Ryoji, Kaku, Kohei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947124/
https://www.ncbi.nlm.nih.gov/pubmed/29316236
http://dx.doi.org/10.1111/dom.13213

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5947124/
https://www.ncbi.nlm.nih.gov/pubmed/29316236
http://dx.doi.org/10.1111/dom.13213

Ejemplares similares